Lipid-altering agents: The future

International Journal of Clinical Practice

Volumn 58, Issue 11, 2004, Pages 1063-1072

  Wierzbicki, Anthony S ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

Cholesterol; HDL; LDL; Risk factor; Therapy; Treatment

Indexed keywords

2 METHYLPROPANETHIOIC ACID S [2 [1 (2 ETHYLBUTYL)CYCLOHEXYLCARBOXAMIDO]PHENYL] ESTER; 4 [(4 BROMO 2 CYANOPHENYL)CARBAMOYL]BENZYLPHOSPHONIC ACID DIETHYL ESTER; AMIODARONE; AMLODIPINE; ANTILIPEMIC AGENT; ATORVASTATIN; AVASIMIBE; CARRIER PROTEIN; CHOLESTEROL ACYLTRANSFERASE; CHOLESTEROL ESTER TRANSFER PROTEIN; CLOFIBRATE; COLESTYRAMINE; EZETIMIBE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; IMPLITAPIDE; LIPOPROTEIN A; MEVINOLIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PITAVASTATIN; PRAVASTATIN; PROBUCOL SUCCINATE; PROTEIN INHIBITOR; ROSUVASTATIN; SIMVASTATIN; SQUALENE SYNTHASE; SQUALENE SYNTHASE INHIBITOR; TAK 475; TESAGLITAZAR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL MODEL; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; HUMAN; MYALGIA; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; REVIEW; RISK FACTOR;

ANTILIPEMIC AGENTS; ARTERIOSCLEROSIS; BILE ACIDS AND SALTS; CARRIER PROTEINS; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, LDL; DNA-BINDING PROTEINS; ENZYMES; FORECASTING; GLYCOPROTEINS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; INTESTINAL ABSORPTION; LIPID METABOLISM; OXIDANTS; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; RECEPTORS, CYTOPLASMIC AND NUCLEAR;

EID: 7744243517     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2004.00087.x     Document Type: Review

References (85)

1. Bucher HC, Griffith LE, Guyatt GH. Systematic review on the risk and benefit of different cholesterol-lowering interventions. Arterioscler Thromb Vasc Biol 1999; 19: 187-95.
2. Wierzbicki AS, Poston R, Ferro A. The lipid and non-lipid effects of statins. Pharmacol Ther 2003; 99: 95-112.
3. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97.
4. Warnick GR, Myers GL, Cooper GR, Rifai N. Impact of the third cholesterol report from the adult treatment panel of the national cholesterol education program on the clinical laboratory. Clin Chem 2002; 48: 11-7.
5. Wierzbicki AS, Mikhailidis DP. Beyond LDL-C - the importance of raising HDL-C. Curr Med Res Opin 2002; 18: 36-44.
6. Wierzbicki AS, Mikhailidis DP, Wray R et al. Statin-fibrate combination: therapy for hyperlipidaemia: a review. Curr Med Res Opin 2003; 19: 155-6.
7. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. The post coronary artery bypass graft trial investigators. N Engl J Med 1997; 336: 153-62.
8. MRC/BHF. Heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
9. McTaggart F, Buckett L, Davidson R et al. Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Am J Cardiol 2001; 87: 28B-32B.
10. Olsson AG, Pears J, McKellar J, Mizan J, Raza A. Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia. Am J Cardiol 2001; 88: 504-8.
11. Chong PH, Yim BT. Rosuvastatin for the treatment of patients with hypercholesterolemia. Ann Pharmacother 2002; 36: 93-101.
12. Wierzbicki AS, Lumb PJ, Chik G. Comparison of therapy with simvastatin 80 mg and 120 mg in patients with familial hypercholesterolaemia. Int J Clin Pract 2001; 55: 673-5.
13. Kajinami K, Mabuchi H, Saito Y. NK-104: a novel synthetic HMG-CoA reductase inhibitor. Expert Opin Investig Drugs 2000; 9 2653-61.
14. Ness GC, Zhao Z, Keller RK. Effect of squalene synthase inhibition on the expression of hepatic cholesterol biosynthetic enzymes, LDL receptor, and cholesterol 7 alpha hydroxylase. Arch Biochem Biophys 1994; 311: 277-85.
15. Hiyoshi H, Yanagimachi M, Ito M et al. Squalene synthase inhibitors reduce plasma triglyceride through a low-density lipoprotein receptor-independent mechanism. Eur J Pharmacol 2001; 431: 345-52.
16. Wierzbicki AS. Editorial: Statins: myalgia and myositis. Br J Cardiol 2002; 9: 193-4.
17. Sharma A, Slugg PH, Hammett JL, Jusko WJ. Clinical pharmacokinetics and pharmacodynamics of a new squalene synthase inhibitor, BMS-188494, in healthy volunteers. J Clin Pharmacol 1998; 38: 1116-21.
18. Bergstrom JD, Kurtz MM, Rew DJ et al. Zaragozic acids: a family of fungal metabolites that are picomolar competitive inhibitors of squalene synthase. Proc Natl Acad Sci USA 1993; 90: 80-4.
19. Amin D, Rutledge RZ, Needle SN et al. RPR 107393, a potent squalene synthase inhibitor and orally effective cholesterol-lowering agent: comparison with inhibitors of HMG-CoA reductase. J Pharmacol Exp Ther 1997; 281: 746-52.
20. Ugawa T, Kakuta H, Moritani H et al. YM-53601, a novel squalene synthase inhibitor, reduces plasma cholesterol and triglyceride levels in several animal species. Br J Pharmacol 2000; 131: 63-70.
21. Wierzbicki AS. Imidazole derivatives as cholesterol-lowering agents. Int J Cardiol 2003; 90: 145-6.
22. Taghibiglou C, Van Iderstine SC, Kulinski A, Rudy D, Adeli K. Intracellular mechanisms mediating the inhibition of apoB-containing lipoprotein synthesis and secretion in HepG2 cells by avasimibe (CI-1011), a novel acyl-coenzyme A: cholesterol acyltransferase (ACAT) inhibitor. Biochem Pharmacol 2002; 63: 349-60.
23. Chang TY, Chang CC, Lin S, Yu C, Li BL, Miyazaki A. Roles of acyl-coenzyme A: cholesterol acyltransferase-1 and -2. Curr Opin Lipidol 2001; 12: 289-96.
24. Burnett JR, Wilcox LJ, Telford DE et al. Inhibition of ACAT by avasimibe decreases both VLDL and LDL apolipoprotein B production in miniature pigs. J Lipid Res 1999; 40: 1317-27.
25. Delsing DJ, Offerman EH, van Duyvenvoorde W et al. Acyl-CoA: cholesterol acyltransferase inhibitor avasimibe reduces atherosclerosis in addition to its cholesterol-lowering effect in ApoE*3-Leiden mice. Circulation 2001; 103: 1778-86.
26. Bocan TM, Mueller SB, Brown EQ et al. HMG-CoA reductase and ACAT inhibitors act synergistically to lower plasma cholesterol and limit atherosclerotic lesion development in the cholesterol-fed rabbit. Atherosclerosis 1998; 139: 21-30.
27. Insull W Jr, Koren M, Davignon J et al. Efficacy and short-term safety of a new ACAT inhibitor, avasimibe, on lipids, lipoproteins, and apolipoproteins, in patients with combined hyperlipidemia. Atherosclerosis 2001; 157: 137-44.
28. Tardif JC, Gregoire J, Lesperance J et al. Design features of the Avasimibe and Progression of coronary Lesions assessed by intravascular UltraSound (A-PLUS) clinical trial. Am Heart J 2002; 144: 589-96.
29. Burnett JR, Huff MW. Avasimibe Pfizer. Curr Opin Invest Drugs 2002; 3: 1328-33.
30. Jamil H, Chu CH, Dickson JK Jr et al. Evidence that microsomal triglyceride transfer protein is limiting in the production of apolipoprotein B-containing lipoproteins in hepatic cells. J Lipid Res 1998; 39: 1448-54.
31. Wetterau JR, Gregg RE, Harrity TW et al. An MTP inhibitor that normalizes atherogenic lipoprotein levels in WHHL rabbits. Science 1998; 282: 751-4.
32. Shiomi M, Ito T. MTP inhibitor decreases plasma cholesterol levels in LDL receptor-deficient WHHL rabbits by lowering the VLDL secretion. Eur J Pharmacol 2001; 431: 127-31.
33. Jin FY, Kamanna VS, Kashyap ML. Niacin accelerates intracellular ApoB degradation by inhibiting triacylglycerol synthesis in human hepatoblastoma (HepG2) cells. Arterioscler Thromb Vasc Biol 1999; 19: 1051-9.
34. Gylling H, Miettinen TA. Cholesterol reduction by different plant stanol mixtures and with variable fat intake. Metabolism 1999; 48: 575-80.
35. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984; 251: 351-64.
36. Leitersdorf E. Selective cholesterol absorption inhibition: a novel strategy in lipid-lowering management. Int J Clin Pract 2002; 56: 116-9.
37. Altmann SW, Davis HR, Jr., Zhu LJ et al. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science 2004; 303: 1201-4.
38. Smart EJ, De Rose RA, Farber SA. Annexin 2-caveolin 1 complex is a target of ezetimibe and regulates intestinal cholesterol transport. Proc Natl Acad Sci USA 2004; 101: 3450-5.
39. Nutescu EA, Shapiro NL. Ezetimibe: a selective cholesterol absorption inhibitor. Pharmacotherapy 2003; 11: 1463-74.
40. Buchwald H, Varco RL, Matts JP et al. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH). N Engl J Med 1990; 323 946-55.
41. Edwards PA, Kast HR, Anisfeld AM. BAREing it all: the adoption of LXR and FXR and their roles in lipid homeostasis. J Lipid Res 2002; 43: 2-12.
42. Higaki J, Hara S, Takasu N et al. Inhibition of ileal Na+/bile acid cotransporter by S-8921 reduces serum cholesterol and prevents atherosclerosis in rabbits. Arterioscler Thromb Vasc Biol 1998; 18: 1304-11.
43. Sacks FM. The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: expert group recommendations. Am J Cardiol 2002; 90: 139-43.
44. Robins SJ, Collins D, Wittes JT et al. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA 2001; 285: 1585-91.
45. Idzior-Walus B, Sieradzki J, Rostworowski W et al. Effects of comicronised fenofibrate on lipid and insulin sensitivity in patients with polymetabolic syndrome X. Eur J Clin Invest 2000; 30: 871-8.
46. Lohray BB, Lohray VB, Bajji AC et al. (-)3-[4-[2-(Phenoxazin-10-yl) ethoxy]phenyl]-2-ethoxypropanoic acid [(-) DRF 2725]: a dual PPAR agonist with potent antihyperglycemic and lipid modulating activity. J Med Chem 2001; 44: 2675-8.
47. Shibata T, Takeuchi S, Yokota S, Kakimoto K, Yonemori F, Wakitani K. Effects of peroxisome proliferator-activated receptor-alpha and -gamma agonist, JTT-501, on diabetic complications in Zucker diabetic fatty rats. Br J Pharmacol 2000; 130: 495-504.
48. Etgen GJ, Oldham BA, Johnson WT et al. A tailored therapy for the metabolic syndrome: the dual peroxisome proliferator-activated receptor-alpha/gamma agonist LY465608 ameliorates insulin resistance and diabetic hyperglycemia while improving cardiovascular risk factors in preclinical models. Diabetes 2002; 51: 1083-7.
49. Yajima K, Hirose H, Fujita H et al. Combination therapy with PPARgamma and PPARalpha agonists increases glucose-stimulated insulin secretion in db/db mice. Am J Physiol Endocrinol Metab 2003; 284 E966-E971.
50. Calkin AC, Thomas MC, Cooper ME. MK-767. Kyorin/Banyu/Merck. Curr Opin Invest Drugs 2003; 4: 444-8.
51. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E, after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet 1999; 354: 447-55.
52. Marchioli R, Barzi F, Bomba E et al. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione. Circulation 2002; 105: 1897-903.
53. Morton RE. Cholesteryl ester transfer protein and its plasma regulator: lipid transfer inhibitor protein. Curr Opin Lipidol 1999; 10: 321-7.
54. Okamoto H, Yonemori F, Wakitani K, Minowa T, Maeda K, Shinkai H. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature 2000; 406: 203-7.
55. de Grooth GJ, Kuivenhoven JA, Stalenhoef AF et al. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study. Circulation 2002; 105: 2159-65.
56. Brousseau ME, Schaefer EJ, Wolfe ML, et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med 2004; 350: 1505-15.
57. Davidson MH, Maki K, Umporowicz D, Wheeler A, Rittershaus C, Ryan U. The safety and immunogenicity of a CETP vaccine in healthy adults. Atherosclerosis 2003; 169: 113-20.
58. Srivastava RA, Srivastava N. High density lipoprotein, apolipoprotein A-I, and coronary artery disease. Mol Cell Biochem 2000; 209: 131-44.
59. Newton RS, Krause BR. HDL therapy for the acute treatment of atherosclerosis. Atheroscler Suppl 2002; 3: 31-8.
60. Chiesa G, Sirtori CR. Apolipoprotein A-IMilano: current perspectives. Curr Opin Lipidol 2003; 14: 159-63.
61. Klon AE, Jones MK, Segrest JP, Harvey SC. Molecular belt models for the apolipoprotein A-I Paris and Milano mutations. Biophys J 2000; 79: 1679-85.
62. Nissan SE, Tsunoda T, Tuzcu EM et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 2003; 290: 2292-300.
63. Mertens A, Holvoet P. Oxidized LDL and HDL: antagonists in atherothrombosis. FASEB J 2001; 15: 2073-84.
64. Packard CJ, O'Reilly DS, Caslake MJ et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med 2000; 343: 1148-55.
65. Blackie JA, Bloomer JC, Brown MJ et al. The identification of clinical candidate SB-480848: a potent inhibitor of lipoprotein-associated phospholipase A (2). Bioorg Med Chem Lett 2003; 13: 1067-70.
66. Shlipak MG, Simon JA, Vittinghoff E et al. Estrogen and progestin, lipoprotein (a), and the risk of recurrent coronary heart disease events after menopause. JAMA 2000; 283: 1845-52.
67. Berglund L, Carlstrom K, Stege R et al. Hormonal regulation of serum lipoprotein (a) levels: effects of parenteral administration of estrogen or testosterone in males. J Clin Endocrinol Metab 1996; 81: 2633-7.
68. Sharp RJ, Perugini MA, Marcovina SM, McCormick SP. A synthetic peptide that inhibits lipoprotein (a) assembly. Arterioscler Thromb Vasc Biol 2003; 23: 502-7.
69. Sundell CL, Somers PK, Meng CQ et al. AGI-1067: a multifunctional phenolic antioxidant, lipid modulator, anti-inflammatory and antiatherosclerotic agent. J Pharmacol Exp Ther 2003; 305 1116-23.
70. Tardif JC. Clinical results with AGI-1067: a novel antioxidant vascular protectant. Am J Cardiol 2003; 91: 41A-9A.
71. Tardif JC, Gregoire J, Schwartz L et al. Effects of AGI-1067 and probucol after percutaneous coronary interventions. Circulation 2003; 107: 552-8.
72. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003; 326: 1419.
73. Kastelein J. What future for combination therapies? Int J Clin Pract Suppl 2003: 45-50.
74. The Lipid Research Clinics Coronary Primary Prevention Trial results II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984; 251: 365-74.
75. WHO cooperative trial on primary prevention of ischaemic heart disease with clofibrate to lower serum cholesterol: final mortality follow-up. Report of the Committee of Principal Investigators. Lancet 1984; 2: 600-4.
76. Helsinki heart study: a controlled coronary prevention trial. Design and baseline findings. Eur Heart J 1987; 8 (Suppl. I): 1-43.
77. Rubins HB, Robins SJ, Collins D et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999; 341: 410-8.
78. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9.
79. Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335: 1001-9.
80. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998; 339 1349-57.
81. Shepherd J, Cobbe SM, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333 1301-7.
82. Downs JR, Clearfield M, Weis S et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279: 1615-22.
83. Stewart WJ, Hoogwerf BJ. Lipid-lowering therapy after coronary artery bypass surgery: the Post-CABG trial. Cleve Clin J Med 1997; 64: 347-51.
84. Athyros VG, Papageorgiou AA, Mercouris BR et al. Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Curr Med Res Opin 2002; 18: 220-8.
85. Sever PS, Dahlof B, Poulter NR et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361: 1149-58.